Navigation Links
Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
Date:11/2/2007

NEW YORK and SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), and Cypress Bioscience, Inc. (Nasdaq: CYPB) will host a webcast to discuss milnacipran clinical data being presented at the American College of Rheumatology annual conference. The webcast, which will include a slide presentation, will occur on November 8, 2007 at 10:00am EST. Representing Forest Laboratories will be Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest and representing Cypress Bioscience will be Dr. Jay Kranzler, Chairman and Chief Executive Officer of Cypress. Also presenting on the webcast will be Dr. Daniel J. Clauw and Dr. Philip Mease, two milnacipran study investigators that will provide an overview of fibromyalgia syndrome and the current challenges faced by both patients and physicians in managing this complex disease, as well as discuss the milnacipran data findings being presented at ACR.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

The webcast can be accessed at the URL: http://phx.corporate- ir.net/phoenix.zhtml?p=irol-eventDetails&c=83198&eventID=1686016 (Due to the length of the link, please copy and paste into you're browser.)

The webcast will also be available on the Forest Laboratories and Cypress Bioscience websites at http://www.frx.com and http://www.cypressbio.com.

A replay of the conference call will be available until December 8, 2007 on both websites.

About Milnacipran:

Milnacipran is a unique dual-reuptake inhibitor, which preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters known to play an essential role in regulating pain and mood. It has been approved for the treatment of depression in over 32 countries and has been used by more than 5 million patients during more than 10 years of commercial availability outside the U.S. Milnacipran is being developed for fibromyalgia in the United States market jointly by Forest and its licensor, Cypress Bioscience, Inc.


'/>"/>
SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird flu threat ruled out: Karnataka Forest Department
2. Will The Tropical Forests Survive The Deforestation Scenario?
3. Higher Health Cost Due to Forest Fires
4. Forest Fire Affects Singapores Air Quality
5. India to Protect Its Forests With the Aid of Austrian NGO
6. Human Induced Nitrogen Deposition Increasing Carbon Sequestration in Forests
7. Deforestation Plays a Critical Role in Climate Change: Study
8. China Unveils Green Plan to Revert Farmland to Forest
9. Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming
10. Dr Reddy’s Laboratories to challenge patents on drug
11. Dr Reddy’s Laboratories launches Hyalosy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Washington, NC (PRWEB) , ... February 12, 2016 , ... ... the surrounding areas, is initiating a charity drive that will raise funds earmarked to ... at John C. Tayloe Elementary School. , “My school is in a low-income area ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Pittsburgh metro area, celebrates the beginning of the latest charity campaign in their ... skills through art. Donations to this worthy cause are currently being accepted at: ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas ... by continuing it’s commitment to act as Agents of Change in the community, ... with area homeless families to fulfill immediate needs and help them move into ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have ... possibilities. CertainTeed, North America’s leading brand of building products, has improved upon its ... in the mobile version of the ColorView® Exterior Style and Color Selector. Created ...
(Date:2/12/2016)... ... ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter ... teens with and without special needs to gather in a safe and supportive environment. Volunteers ... will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Inc., a medical device company that pioneered the use of the ... device indicated for fusion for certain disorders of the sacroiliac (SI) ... Contractor (MAC) covering the states of Connecticut , ... Massachusetts , Minnesota , ... Rhode Island , Vermont and ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
Breaking Medicine Technology: